Pre- and intratherapeutical ibritumomab tiuxetan Zevalin® dosimetry in childhood

Nuklearmedizin 2013; 52(05): N58-N59
DOI: 10.1055/s-0038-1625751

Case report

Schattauer GmbH

Pre- and intratherapeutical ibritumomab tiuxetan Zevalin^® dosimetry in childhood

C. Happel

¹Department of Nuclear Medicine, University Medical Centre Frankfurt

,

J. Diener

¹Department of Nuclear Medicine, University Medical Centre Frankfurt

,

W. T. Kranert

¹Department of Nuclear Medicine, University Medical Centre Frankfurt

,

B. Bockisch

¹Department of Nuclear Medicine, University Medical Centre Frankfurt

,

J. Pinkert

²Bayer Vital GmbH, Leverkusen, Germany

,

F. Grünwald

¹Department of Nuclear Medicine, University Medical Centre Frankfurt

References
1 Cooney-Qualter E, Krailo M, Angiolillo A. et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma. Clin Cancer Res 2007; 13: 5652s-5660s.
2 Fischer M, Grünwald F, Knapp WH. et al. Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin’s lymphoma. Nuklearmedizin 2009; 48: 215-220.
3 Grgic A, Nestle U, Scheidhauer K. et al. Retrospective web-based multicenter evaluation of ¹⁸F-FDGPET and CT derived predictive factors. Nuklearmedizin 2011; 50: 39-47.
4 Lassmann M, Chiesa C, Flux G. et al. EANM Dosimetry Committee guidance document. Eur J Nucl Med Mol Imaging 2011; 38: 192-200.
5 Tennvall J, Fischer M, Bischof Delaloye A. et al. EANM procedure guideline of radio-immunotherapy for B-cell lymphoma with ⁹⁰Y-radiolabeled ibritumomab tiuxetan (Zevalin^®). Eur J Nucl Med Mol Imaging 2007; 34: 616-622.